Could a smaller HPV vaccine dose still protect adults?
NCT ID NCT05291871
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving a smaller (one-fifth) dose of the HPV vaccine, either into the skin or muscle, can still trigger a strong immune response in adults aged 27 to 45. About 92 men and women in Seattle will have their antibody levels checked over a year. The goal is to see if lower doses could be an option to save costs and stretch vaccine supplies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Washington Virology Research Clinic
Seattle, Washington, 98104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a personalized video and phone call get more teens the HPV vaccine?
- Can a daily supplement help the body fight off HPV?
- At-Home HPV tests could save lives of women with HIV
- New immune therapy aims to train body to clear HPV
- Could a tiny HPV shot still protect? small study tests lower dose
- New Self-Sampling and digital colposcopy could speed up cervical cancer detection